Evidence map›Paper›PMID 37296618›Full record

ArticleCells2023

Extracellular Vesicles Released by Genetically Modified Macrophages Activate Autophagy and Produce Potent Neuroprotection in Mouse Model of Lysosomal Storage Disorder, Batten Disease.

Nazira El-Hage, Matthew J Haney, Yuling Zhao, Myosotys Rodriguez, Zhanhong Wu, Mori Liu, Carson J Swain, Hong Yuan, Elena V Batrakova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Extracellular Vesicles from Immune Cells: A Biomedical Perspective.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nazira El-HageDepartment of Immunology and Nanomedicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
Matthew J HaneyCenter for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Yuling ZhaoCenter for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Myosotys RodriguezDepartment of Immunology and Nanomedicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.ORCID 0000-0002-3925-9023
Zhanhong WuDepartment of Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Mori LiuEshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Carson J SwainEshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Hong YuanDepartment of Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0000-0002-0535-3214
Elena V BatrakovaCenter for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-9386-3790
University of North Carolina at Chapel Hill · USFlorida International University · US

Funding

Cell-based Platform for Gene Delivery to the BrainR01NS102412 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BATRAKOVA, ELENA · 2018 to 2022
$1.7M
Extracellular Vesicles for CNS Delivery of Therapeutic Enzymes to Treat Lysosomal Storage DisordersR01NS112019 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BATRAKOVA, ELENA · 2019 to 2023
$1.5M
NINDS NIH HHS R01 NS102412NINDS NIH HHS R01 NS112019
6 · The paper itself

Abstract

Over the recent decades, the use of extracellular vesicles (EVs) has attracted considerable attention. Herein, we report the development of a novel EV-based drug delivery system for the transport of the lysosomal enzyme tripeptidyl peptidase-1 (TPP1) to treat Batten disease (BD). Endogenous loading of macrophage-derived EVs was achieved through transfection of parent cells with TPP1-encoding

Indexed as

Extracellular VesiclesLysosomal Storage DiseasesNeuronal Ceroid-LipofuscinosesAminopeptidasesAnimalsAutophagyDipeptidyl-Peptidases and Tripeptidyl-PeptidasesLipofuscinLysosomesMiceNeuroprotectionSerine ProteasesTripeptidyl-Peptidase 1AminopeptidasesDipeptidyl-Peptidases and Tripeptidyl-PeptidasesLipofuscinSerine ProteasesTripeptidyl-Peptidase 1autophagyBatten diseasedrug deliveryextracellular vesicleslysosomal storage disordersneuroprotection

Identifiers

PMID37296618
PMCPMC10252192
OpenAlexW4378715744

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.